Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Open-label, continuation study
|Condition or Disease||Intervention/Treatment||Phase|
This is a multicenter, open-label, non-randomized, study of TRC105 in patients that have completed a previous TRC105 study and are judged by the investigator to have the potential to benefit from continued TRC105 therapy.
Primary Outcome Measures
Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought to have potential to derive clinical benefit from continued treatment with TRC105 in the opinion of the parent study investigator.
Willing and able to consent for self to participate in study
Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
18 years of age or older
ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last dose of TRC105 in the parent TRC105 study
Any clinical event that would make TRC105 therapy inappropriate under the parent protocol
Current treatment in another clinical study
Pregnant or breastfeeding
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, would make the subject inappropriate for entry into the study
Contacts and Locations
|1||UCLA||Santa Monica||California||United States||90404|
Sponsors and Collaborators
- Tracon Pharmaceuticals Inc.
- Study Director: Charles Theuer, MD, Tracon Pharmaceuticals Inc.
Study Documents (Full-Text)None provided.